Effectiveness of a pharmacist-delivered smoking cessation program in the State of Qatar: a randomized controlled trial

Maguy Saffouh El Hajj, Nadir Kheir, Ahmad Mohd Al Mulla, Rula Shami, Nadia Fanous, Ziyad R Mahfoud, Maguy Saffouh El Hajj, Nadir Kheir, Ahmad Mohd Al Mulla, Rula Shami, Nadia Fanous, Ziyad R Mahfoud

Abstract

Background: Cigarette smoking is one of the major preventable causes of death and diseases in Qatar. The study objective was to test the effect of a structured smoking cessation program delivered by trained pharmacists on smoking cessation rates in Qatar.

Methods: A prospective randomized controlled trial was conducted in eight ambulatory pharmacies in Qatar. Eligible participants were smokers 18 years and older who smoked one or more cigarettes daily for 7 days, were motivated to quit, able to communicate in Arabic or English, and attend the program sessions. Intervention group participants met with the pharmacists four times at 2 to 4 week intervals. Participants in the control group received unstructured brief smoking cessation counseling. The primary study outcome was self-reported continuous abstinence at 12 months. Analysis was made utilizing data from only those who responded and also using intent-to-treat principle. A multinomial logistic regression model was fitted to assess the predictors of smoking at 12 months. Analysis was conducted using IBM-SPSS® version 23 and STATA® version 12.

Results: A total of 314 smokers were randomized into two groups: intervention (n = 167) and control (n = 147). Smoking cessation rates were higher in the intervention group at 12 months; however this difference was not statistically significant (23.9% vs. 16.9% p = 0.257). Similar results were observed but with smaller differences in the intent to treat analysis (12.6% vs. 9.5%, p = 0.391). Nevertheless, the daily number of cigarettes smoked for those who relapsed was significantly lower (by 4.7 and 5.6 cigarettes at 3 and 6 months respectively) in the intervention group as compared to the control group (p = 0.041 and p = 0.018 respectively). At 12 months, the difference was 3.2 cigarettes in favor of the intervention group but was not statistically significant (p = 0.246). Years of smoking and daily number of cigarettes were the only predictors of smoking as opposed to quitting at 12 months (p = 0.005; p = 0.027 respectively).

Conclusions: There was no statistically significant difference in the smoking cessation rate at 12 months between the groups. However, the smoking cessation program led to higher (albeit non-significant) smoking cessation rates compared with usual care. More research should be conducted to identify factors that might improve abstinence.

Trial registration: Clinical Trials NCT02123329 . Registration date 20 April 2014.

Keywords: Intervention; Pharmacist; Qatar; Randomized controlled trial; Smoking cessation; Tobacco cessation.

Figures

Fig. 1
Fig. 1
Participant flow chart

References

    1. The World Health Organization. Tobacco factsheet. . Accessed 2 Sept 2016.
    1. The World Health Organization. Report on the Global Tobacco Epidemic, 2011:warning about the dangers of tobacco. . (2011). Accessed 2 Sept 2016.
    1. The World Health Organization. Fact sheet about health benefits of smoking cessation. . (2015). Accessed 22 May 2016.
    1. The World Health Organization. Tobacco Free Initiative (TFI). . Accessed 22 May 2016.
    1. U.S. Department of Health and Human Services. Treating tobacco use and dependence: 2008 update.2008. . Accessed 22 May 2016.
    1. Aquilino ML, Farris KB, Zillich AJ, Lowe JB. Smoking-cessation services in Iowa community pharmacies. Pharmacotherapy. 2003;23:666–73. doi: 10.1592/phco.23.5.666.32192.
    1. Saba M, Diep J, Saini B, Dhippayom T. Meta-analysis of the effectiveness of smoking cessation interventions in community pharmacy. J Clin Pharm Ther. 2014;39:240–7. doi: 10.1111/jcpt.12131.
    1. Vial RJ, Jones TE, Ruffin RE, Gilbert AL. Smoking cessation program using nicotine patches: linking hospital to the community. J Pharm Pract Res. 2002;32:57–62. doi: 10.1002/jppr200232157.
    1. Carroll P, Rois R, Sarson D, Flynn J. A community pharmacy based smoking cessation program using transdermal nicotine replacement therapy: actions and outcomes. Aust Pharmacist. 2000;19:51–5.
    1. Zillich AJ, Ryan M, Adams A, Yeager B, Farris K. Effectiveness of a pharmacist-based smoking-cessation program and its impact on quality of life. Pharmacotherapy. 2002;22:759–65. doi: 10.1592/phco.22.9.759.34073.
    1. Dent LA, Harris KJ, Noonan CW. Randomized trial assessing the effectiveness of a pharmacist-delivered program for smoking cessation. Ann Pharmacother. 2009;43:194–201. doi: 10.1345/aph.1L556.
    1. Smith MD, McGhan WF, Lauger G. Pharmacist counseling and outcomes of smoking cessation. Am Pharm. 1995;NS35:20–9. doi: 10.1016/S0160-3450(15)30095-7.
    1. Kennedy DT, Giles JT, Chang ZG, Small RE, Edwards JH. Results of a smoking cessation clinic in community pharmacy practice. J Am Pharm Assoc. 2002;42:51–6. doi: 10.1331/108658002763538071.
    1. Dent LA, Scott JG, Lewis E. Pharmacist-managed tobacco cessation program in Veterans Health Administration community-based outpatient clinic. J Am Pharm Assoc. 2004;44:700–15. doi: 10.1331/1544345042467290.
    1. The International Pharmaceutical Federation. FIP Statement of Policy: the Role of the Pharmacist in Promoting a Tobacco Free Future. (2003). Accessed 22 May 2016.
    1. Europharm Forum. Pharmacists and Actions on Tobacco. (1998). Accessed 22 May 2016.
    1. Hudmon KS, Corelli RL. ASHP therapeutic position statement on the cessation of tobacco Use. Am J Health Syst Pharm. 2009;66:291–307. doi: 10.2146/ajhp070303.
    1. The World Health Organization. Global Adult Tobacco Survey Qatar. (2013). Accessed 22 May 2016.
    1. The World Health Organization. Global Youth Tobacco Survey Qatar. (2014). Accessed 22 May 2016.
    1. The World Health Organization. Qatar: WHO Statistical Profile. (2015). Accessed 22 May 2016.
    1. Bener A, Ayub H, Kakil R, Ibrahim W. Patterns of cancer incidence among the population of Qatar: a worldwide comparative study. Asian Pac J Cancer Prev. 2008;9:19–24.
    1. Smoking—Addressing a National Epidemic. Available at: . Accessed 22 May 2016.
    1. Supreme Council of Health. TOBACCO CESSATION ACTION PLAN: (2015–2016). . Accessed 22 May 2016.
    1. El Hajj MS, Al Nakeeb RR, Al-Qudah RA. Smoking cessation counseling in Qatar: community pharmacists’ attitudes, role perceptions and practices. Int J Clin Pharm. 2012;34:667–76. doi: 10.1007/s11096-012-9663-x.
    1. El Hajj MS, Kheir N, Al Mulla AM, Al-Badriyeh D, Al Kaddour A, Mahfoud ZR, et al. Assessing the effectiveness of a pharmacist-delivered smoking cessation program in the State of Qatar: study protocol for a randomized controlled trial. Trials. 2015;16:65. doi: 10.1186/s13063-015-0570-z.
    1. UpToDate. Behavioral approaches to smoking cessation. . Accessed 22 May 2016.
    1. Kennedy DT, Small RE. Development and implementation of a smoking cessation clinic in community pharmacy practice. J Am Pharm Assoc. 2002;42:83–92. doi: 10.1331/108658002763538116.
    1. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Br J Addict. 1991;86:1119–27. doi: 10.1111/j.1360-0443.1991.tb01879.x.
    1. Al Mohamed HI, Amin TT. Pattern and prevalence of smoking among students at King Faisal University, Al Hassa. Saudi Arabia EMHJ. 2010;16:56–64.
    1. Asfar MD, Vander MW, Maziak W, Hammal F, Eissenberg T, Ward KD. Outcomes and adherence in Syria’s first smoking cessation trial. Am J Health Behav. 2008;32:146–56. doi: 10.5993/AJHB.32.2.4.
    1. Hudmon KS, Berger BA. Pharmacy applications of the transtheoretical model in smoking cessation. Am J Health Syst Pharm. 1995;52:282–7.
    1. DRUGDEX® Evaluations. Nicotine. . Accessed 22 May 2016.
    1. DRUGDEX® Evaluations: Nicotine polacrilex. . Accessed 22 May 2016.
    1. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med. 2001;163:1693–1722. doi: 10.1164/ajrccm.163.7.2009041.
    1. Schulz KF, Altman DG, Moher D, for the CONSORT Group CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. doi: 10.1136/bmj.c332.
    1. Borelli B, Hogan J, Bock B, Pinto B, Roberts M, Marcus B. Predictors of quitting and dropout among women in a clinic-based smoking cessation program. Psychol Addict Behav. 2002;16:22–7. doi: 10.1037/0893-164X.16.1.22.
    1. Maguire TA, McElnay JC, Drummond A. A randomized controlled trial of a smoking cessation intervention based in community pharmacies. Addiction. 2001;96:325–31. doi: 10.1046/j.1360-0443.2001.96232516.x.
    1. Sinclair HK, Bond CM, Lennox AS, Silcock J, Winfield AJ, Donnan PT. Training pharmacists and pharmacy assistants in the stage-of-change model of smoking cessation: a randomized controlled trial in Scotland. Tob Control. 1998;7:253–61. doi: 10.1136/tc.7.3.253.
    1. Thomas D, Abramson MJ, Bonevski B, Taylor S, Poole SG, Paul E, et al. Integrating smoking cessation into routine care in hospitals-a randomized controlled trial. Addiction. 2016;111:714–23. doi: 10.1111/add.13239.
    1. El Hajj MS, Al-Saeed HS, Khaja M. Qatar pharmacists’ understanding, attitudes, practice and perceived barriers related to providing pharmaceutical care. Int J Clin Pharm. 2016;38:330–43. doi: 10.1007/s11096-016-0246-0.
    1. Vangeli E, Stapleton J, Smit ES, Borland R, West R. Predictors of attempts to stop smoking and their success in adult general population samples: a systematic review. Addiction. 2011;106:2110–21. doi: 10.1111/j.1360-0443.2011.03565.x.
    1. Bauld L, Boyd KA, Briggs AH, Chesterman J, Ferguson J, Judge K, et al. One-year outcomes and a cost-effectiveness analysis for smokers accessing group-based and pharmacy-led cessation services. Nicotine Tob Res. 2011;13:135–45. doi: 10.1093/ntr/ntq222.
    1. Roth MT, Westman EC. Use of bupropion SR in a pharmacist-managed outpatient smoking-cessation program. Pharmacotherapy. 2001;21:636–41. doi: 10.1592/phco.21.6.636.34548.
    1. Hyland A, Li Q, Bauer JE, Giovino GA, Steger C, Cummings KM. Predictors of cessation in a cohort of current and former smokers followed over 13 years. Nicotine Tob Res. 2004;6(Suppl 3):S363–9. doi: 10.1080/14622200412331320761.
    1. Khan N, Anderson JR, Du J, Tinker D, Bachyrycz AM, Namdar R. Smoking cessation and its predictors: results from a community-based pharmacy tobacco cessation program in New Mexico. Ann Pharmacother. 2012;46:1198–204. doi: 10.1345/aph.1P146.
    1. Shen X, Bachyrycz A, Anderson JR, Tinker D, Raisch DW. Quitting patterns and predictors of success among participants in a tobacco cessation program provided by pharmacists in New Mexico. J Manag Care Spec Pharm. 2014;20:579–87.
    1. Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce J, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2013;5:CD000165.
    1. Gorin SS, Heck JE. Meta-analysis of the efficacy of tobacco counseling by health care providers. Cancer Epidemiol Biomarkers Prev. 2004;13:2012–22.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera